Ubiquitin-Proteasome System

Overview

Inside every eukaryotic cell, thousands of proteins are produced, used, and discarded every minute. The ubiquitin-proteasome system (UPS) is the main selective disposal pathway — responsible for about 80-90% of intracellular protein turnover. It degrades short-lived regulatory proteins, misfolded or damaged proteins, and proteins tagged for specific signaling outcomes. Loss of ubiquitin system components is generally lethal; defects in individual components underlie neurodegeneration, cancer, autoimmunity, and metabolic disease.

Beyond degradation, ubiquitin and ubiquitin-like modifiers (SUMO, NEDD8, ISG15) regulate protein localization, activity, interactions, and signaling in nearly every pathway covered in this wiki — from the DNA damage response and unfolded protein response to NF-κB and apoptosis.

How It Works

Ubiquitin and the E1-E2-E3 Cascade

Ubiquitin is a 76-amino-acid protein that is covalently attached to substrate lysines through an isopeptide bond via a three-enzyme cascade:

• E1 (ubiquitin-activating enzyme): uses ATP to form a thioester bond with ubiquitin's C-terminal glycine. Humans have two E1s (UBA1, UBA6).
• E2 (ubiquitin-conjugating enzymes): receive ubiquitin from E1 in a thioester exchange. There are ~40 E2s in humans, each with partial specificity.
• E3 (ubiquitin ligases): provide substrate specificity by bringing E2 and substrate together. Over 600 E3s exist, divided into RING (most), HECT, and RBR subfamilies.

Polyubiquitin chains are built on one of ubiquitin's seven lysines (K6, K11, K27, K29, K33, K48, K63) or its N-terminal methionine (M1 linear chains), giving the "ubiquitin code" — each linkage topology encodes a different fate:

• K48-linked chains → proteasomal degradation (the canonical signal).
• K63-linked chains → signaling and trafficking (notably in NF-κB and DNA repair).
• M1 linear chains → inflammation and immune signaling.
• K11 chains → cell cycle control.
• Monoubiquitination → receptor trafficking, histone modification.

The 26S Proteasome

The 26S proteasome is a ~2.5 MDa molecular machine with two components:

• 20S core particle — barrel-shaped, with threefold proteolytic activity (caspase-like β1, trypsin-like β2, chymotrypsin-like β5). Substrates are degraded inside the sequestered lumen to small peptides.
• 19S regulatory particle — caps the 20S ends, recognizes ubiquitinated substrates, removes ubiquitin (via DUBs like Rpn11, USP14, UCH37), unfolds the substrate with ATPase activity, and threads it into the 20S.

Specialized proteasome variants (immunoproteasome, thymoproteasome) produce peptides optimized for MHC class I presentation.

Deubiquitinases (DUBs)

About 100 DUBs remove, trim, or edit ubiquitin chains, allowing the system to be reversible and dynamic. DUBs include USP, UCH, OTU, MJD, and MINDY families, each with distinct linkage preferences.

Biological Roles

Protein Quality Control

The UPS works with autophagy, the unfolded protein response, and chaperone networks to maintain proteostasis. ER-associated degradation (ERAD) is a specialized UPS branch that retrotranslocates misfolded ER proteins for degradation.

Cell Cycle

APC/C and SCF are the two paradigmatic cell-cycle E3s — APC/C targets cyclins and securin for mitotic progression, SCF targets G1 cyclins and CDK inhibitors.

Signaling

The UPS controls:

• NF-κB — IκB degradation (K48), NEMO ubiquitination (K63, M1).
• p53 — MDM2-driven degradation.
• Wnt signaling — β-catenin degradation by β-TrCP.
• Hedgehog — GLI processing.
• Hippo — YAP/TAZ turnover.
• DNA damage response — RNF8/RNF168 histone ubiquitination.

Immunity

Peptide products from proteasomal degradation are loaded onto MHC class I for CD8 T cell surveillance. DUBs and E3s also regulate innate immune signaling and inflammation.

Relevance to Peptides

• Proteasome peptide substrates: the proteasome itself generates peptides, many of which are the MHC class I repertoire and some of which retain bioactivity.
• Peptide-based E3 inhibitors and PROTACs: peptide-mimetic degraders and stapled peptides that recruit E3s to neosubstrates are a major drug discovery frontier. Original PROTAC concepts began with peptide-based recruitment of β-TrCP; the field has since moved toward small-molecule degraders, but peptide PROTACs remain valuable for challenging targets.
• Ubiquitin-binding peptides and probes: tools for dissecting the ubiquitin code in research.
• Proteasome inhibitor peptides: bortezomib (boronic acid peptide), carfilzomib (epoxyketone peptide), and ixazomib are all clinically approved peptide-based proteasome inhibitors, central to multiple myeloma therapy.

Therapeutic Implications

Clinical UPS-targeted therapies include:

• Proteasome inhibitors — bortezomib, carfilzomib, ixazomib (multiple myeloma, mantle cell lymphoma).
• IMiDs (thalidomide, lenalidomide, pomalidomide) — molecular glues that redirect the CRBN-CUL4 E3 ligase to degrade neosubstrates such as IKZF1/3.
• MDM2 inhibitors — restoring p53 in p53 wild-type tumors, stapled peptides included.
• PROTACs and molecular glues — an emerging class that induces targeted protein degradation of previously "undruggable" targets.
• DUB inhibitors — in development across oncology, neurodegeneration, and inflammation.

Current Questions

How the ubiquitin code is read with high fidelity, how to drug specific E3-substrate interfaces in a given tissue context, and how the UPS interacts with autophagy and apoptosis under stress remain central questions. Expanding the PROTAC toolbox — including peptide PROTACs, bifunctional peptides, and delivery-enabled degraders — is one of the most active areas of chemical biology and drug development.